Last reviewed · How we verify

Bupivacaine/epinephrine/dexamethasone

Cedars-Sinai Medical Center · FDA-approved active Small molecule

This is a combination injection containing bupivacaine (local anesthetic), epinephrine (vasoconstrictor), and dexamethasone (corticosteroid) that blocks nerve conduction, maintains local drug concentration, and reduces inflammation at the injection site.

This is a combination injection containing bupivacaine (local anesthetic), epinephrine (vasoconstrictor), and dexamethasone (corticosteroid) that blocks nerve conduction, maintains local drug concentration, and reduces inflammation at the injection site. Used for Local anesthesia for surgical and procedural use.

At a glance

Generic nameBupivacaine/epinephrine/dexamethasone
Also known asDecadron
SponsorCedars-Sinai Medical Center
Drug classLocal anesthetic combination
TargetVoltage-gated sodium channels (bupivacaine); alpha-1 adrenergic receptors (epinephrine); glucocorticoid receptor (dexamethasone)
ModalitySmall molecule
Therapeutic areaAnesthesia/Pain Management
PhaseFDA-approved

Mechanism of action

Bupivacaine works by blocking sodium channels in nerve fibers, preventing action potential propagation and producing local anesthesia. Epinephrine causes vasoconstriction, which prolongs anesthetic duration and reduces systemic absorption. Dexamethasone, a corticosteroid, provides anti-inflammatory effects to reduce post-operative pain and swelling at the injection site.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: